Practical Approaches To Clinical Trial Diversity

Diversity in clinical trials is an increasingly important issue, gaining momentum in the industry as reflected in a Citeline webinar discussing best practices and the FDA’s new diversity requirements. Panelists, including representatives from Bristol Myers Squibb, GSK, Pfizer, and AbbVie, highlighted the need for tailored recruitment strategies to reflect population demographics better.

As noted during the event, companies are focusing on underrepresented groups, such as racial minorities, sexual and gender minorities, and people with disabilities. Efforts include reviewing eligibility criteria, building patient partnerships, and enhancing retention. GSK, for example, aims to meet diversity goals in 50% of its Phase 3 trials, while Pfizer is revising its inclusion criteria to improve recruitment.

While all panelists agreed that diversity efforts must be ongoing, adaptable, and collaborative to ensure long-term impact in developing more inclusive and effective medical therapies, progress is visible. Still, more work remains to fully address this complex issue.

Learn more by downloading the article below.